profit from every ₹100 of sales.
₹0₹100
Metropolis Healthcare
₹576.15-1.06% today
+20.1% in 1 year
1-year low ₹421.751-year high ₹602.10
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2026.
0%20% a year
You pay ₹62.92 for every ₹1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Metropolis Healthcare sold, what it kept, and what it did with the cash.
Sales went from ₹11.5 billion in 2023 to ₹16.5 billion in 2026, with ₹1.90 billion of profit last year.
SalesProfit
Metropolis Healthcare handed back 7% of the cash it generated last year.
₹207M
Free cash flow 2026₹3.0B
Bought back its own shares–
Paid as dividends₹207M
Cash vs. debt₹548M vs. ₹2.3B
Metropolis Healthcare vs. similar companies
Metropolis Healthcare grows the fastest of these 5 and is the most expensive for its profits.
| Company | Profit from ₹100 of sales | Sales growth a year | Price per ₹1 of profit |
|---|---|---|---|
| Metropolis Healthcare | 62.9× · Very expensive | ||
 Thermo Fisher Scientific | 39.7× · Expensive | ||
 Danaher | 45.8× · Expensive | ||
 WuXi AppTec | 26.5× · Fair price | ||
 Lonza Group | No profit yet |
AI analysis
An AI analyst reads Metropolis Healthcare's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 11,482 | 12,077 | 13,312 | 16,458 | |
| 8,845 | 9,470 | 10,523 | 12,983 | |
| 2,088 | 2,034 | 1,943 | 2,671 | |
| 3,035 | 2,917 | 3,181 | 4,174 | |
| 1,429 | 1,278 | 1,450 | 1,900 | |
| 6.95 | 6.22 | 7.04 | 9.19 | |
| 77.0% | 78.4% | 79.1% | 78.9% | |
| 18.2% | 16.8% | 14.6% | 16.2% | |
| 12.4% | 10.6% | 10.9% | 11.5% |
Balance sheet
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 15,016 | 15,551 | 18,673 | 21,381 |
| Cash | 688 | 626 | 395 | 548 |
| Total debt | 2,664 | 1,971 | 2,041 | 2,319 |
| Total liabilities | 5,109 | 4,558 | 5,327 | 6,135 |
| 9,882 | 10,962 | 13,310 | 15,132 | |
| 205 | 206 | 206 | 207 | |
| 12.8% | 11.4% | 10.2% | 12.2% | |
| 14.5% | 11.7% | 10.9% | 12.6% |
Cash flow
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 2,471 | 2,641 | 2,627 | 3,507 | |
| 526 | 638 | 686 | 512 | |
| 1,945 | 2,003 | 1,941 | 2,995 | |
| Dividends paid | 410 | 205 | – | 207 |
| – | – | – | – | |
| 3 | 14 | 70 | 81 |
Valuation
- 62.9×
- –
- 6.46
- 7.1×
- 7.3×
- 39.9×
- 29.1×
- 2.5%
- 1.6%
- 0.2%
Profitability
- 78.9%
- 16.2%
- 11.5%
- –
- 12.2%
- 11.7%
- –
- –
- –
- –
Growth
- +12.8%
- +9.7%
- –
- –
- +0.2%
Financial health
- 0.4×
- 0.15
- –
- 11.6×
- 1.40
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 20%of 958
Top 31%of 888
Bottom 17%of 600
Top 43%of 889
Top 39%of 987
0.2%of the share price, paid each year
On $1,000 invested$2a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
10.9% of its profit
Room to growStretchedMore than it earns: 6.9%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
59No pass
Benjamin Graham
37No pass
Philip Fisher
54No pass
Peter Lynch
36No pass
Joel Greenblatt
11No pass
Charlie Munger
51No pass
Terry Smith
49No pass
Questions about Metropolis Healthcare
Is Metropolis Healthcare a good stock to buy?
A solid business, priced as if everything goes right. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Metropolis Healthcare AI analysis
What does Metropolis Healthcare do?
Metropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India, Africa, South Asia, the Middle East, and internationally. It is in Diagnostics & Research, based in Mumbai, India.
Does Metropolis Healthcare pay a dividend?
Yes. At today's price the dividend is 0.2% a year, about 11% of its yearly profit. In 2026 it paid out ₹207 million in dividends.
Is Metropolis Healthcare stock halal?
Yes. Metropolis Healthcare passes our halal screen: its business is permitted and its debt is 2% of its market value, under the 30% limit. How we check
How has Metropolis Healthcare stock done over the past year?
Up 20.1% over the past twelve months, to ₹576.15. It traded between ₹421.75 and ₹602.10 and is 4.3% below its high.
Who are Metropolis Healthcare's competitors?
The largest listed companies in the same industry are Thermo Fisher Scientific, Danaher, WuXi AppTec and Lonza Group. The peers table on this page compares their profit, growth and price with Metropolis Healthcare's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.